– UK, London – Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies, today announced the appointment of Dr. Rob Iannone to its Board as a Non-Executive Director, effective on June 15, 2023, bringing a wealth of experience in the life science industry, having worked across a broad range of therapeutic areas and phases of development at Jazz Pharmaceuticals plc, Immunomedics, Inc., AstraZeneca plc and Merck & Co., Inc.
“We are pleased to welcome Rob to Autolus. Rob brings broad experience of drug development and regulatory know-how from his long career in oncology. At a time when we are shaping the product profile for obe-cel beyond ALL and preparing for a BLA filing in r/r adult ALL towards the end of the year, his expertise and knowledge will be invaluable,” said CEO, Dr. Christian Itin.
About Dr. Robert Iannone
Dr. Iannone is EVP of Global Head of Research & Development at Jazz Pharmaceuticals plc. Before joining Jazz Pharmaceuticals, Dr. Iannone served as Head of Research and Development and CMO of Immunomedics, Inc. He previously served as SVP and Head of Immuno-oncology, Global Medicines Development, and the Global Products VP at AstraZeneca plc and held several management roles at Merck & Co., Inc., culminating in his role as Executive Director and Section Head of Oncology Clinical Development. Before then, Dr. Iannone served as an Assistant Professor of Pediatrics at the University of Pennsylvania School of Medicine.
“I am delighted to join the Board of Autolus at such a pivotal time in the Company’s development,” said Dr. Iannone. “Obe-cel has the potential to transform the outlook for adult patients with acute lymphoblastic leukemia, and behind that, there is a pipeline of CAR T-cell products and technologies, which can impact more broadly on the treatment paradigm for both liquid and solid tumors.”
Dr. Iannone has also held senior governance and government health advisory roles. He currently serves on the Board of Directors of iTeos Therapeutics and previously served on the Board of Directors of Jounce Therapeutics (acquired by Concentra Biosciences in 2023 for $96.46 million). He has served on the Cancer Steering Committee of the Biomarkers Consortium/Foundation for the National Institutes of Health since 2011 and currently sits on the executive committee of the Biomarkers Consortium. Dr. Iannone received an MD from Yale University and an MSCE from University of Pennsylvania. He completed his Residency and Chief Residency in Pediatrics and a Fellowship in Pediatric Hematology-Oncology at Johns Hopkins University.
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T-cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled, and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
Source: https://www.autolus.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
